JBBS  Vol.5 No.6 , June 2015
Green Tea Consumption Reduces Oxidative Stress in Parkinson’s Disease Patients
Oxidative stress is one of the underlying causes of Parkinson’s disease (PD). Because of its antioxidant effect, we hypothesize that green tea consumption (3 cups daily for 3 months) would improve antioxidant status and reduces oxidative damage in Parkinson’s disease. Fifteen subjects who were within the first five years of PD, on stable PD medication, and not regular green tea consumers were recruited. Iron status, oxidative stress and PD status were evaluated before and after 3 months of green tea consumption. Hemoglobin, serum iron, iron saturation and ferritin concentrations were used to assess iron status. Antioxidant enzymes including catalase, superoxide dismutase (SOD), and glutathione peroxidase (GPx) were measured to determine antioxidant status. Lipid peroxidation and protein carbonyls were measured as oxidative damage markers. There were no changes in total motor scores of the Unified Parkinson’s Disease Rating Scale (UPDRS), PDQ-39 total scores and various iron status markers after 3 months. Catalase (p < 0.05) and SOD activities (p < 0.005) were increased significantly indicating an improvement of antioxidant status. Both lipid peroxidation and protein carbonyls decreased by ~52% (p < 0.01) with green tea consumption, indicating less oxidative stress. In conclusion, 3 cups of green tea consumption for 3 months can improve antioxidant status and reduce oxidative damage in PD patients. Further studies are needed to determine if these changes result in slowing the disease progression.

Cite this paper
Chen, D. , Zhou, Y. , Lyons, K. , Pahwa, R. and Reddy, M. (2015) Green Tea Consumption Reduces Oxidative Stress in Parkinson’s Disease Patients. Journal of Behavioral and Brain Science, 5, 194-202. doi: 10.4236/jbbs.2015.56020.
[1]   Dias, V., Junn, E. and Mouradian, M.M. (2013) The Role of Oxidative Stress in Parkinson’s Disease. Journal of Parkinson’s Disease, 3, 461-491.

[2]   Hwang, O. (2013) Role of Oxidative Stress in Parkinson’s Disease. Experimental Neurobiology, 22, 11-17.

[3]   Gerlach, M., Double, K.L., Ben-Shachar, D., Zecca, L., Youdim, M.B. and Riederer, P. (2003) Neuromelanin and Its Interaction with Iron as a Potential Risk Factor for Dopaminergic Neurodegeneration Underlying Parkinson’s Disease. Neurotoxicity Research, 5, 35-44.

[4]   Gorell, J.M., Ordidge, R.J., Brown, G.G., Deniau, J.C., Buderer, N.M. and Helpern, J.A. (1995) Increased Iron-Related MRI Contrast in the Substantia Nigra in Parkinson’s Disease. Neurology, 45, 1138-1143.

[5]   Atasoy, H.T., Nuyan, O., Tunc, T., Yorubulut, M., Unal, A.E. and Inan, L.E. (2004) T2-Weighted MRI in Parkinson’s Disease; Substantia Nigra Pars Compacta Hypointensity Correlates with the Clinical Scores. Neurology India, 52, 332-337.

[6]   Gilgun-Sherki, Y., Melamed, E. and Offen, D. (2001) Oxidative Stress Induced-Neurodegenerative Diseases: The Need for Antioxidants That Penetrate the Blood Brain Barrier. Neuropharmacology, 40, 959-975.

[7]   Guidetti, C., Paracchini, S., Lucchini, S., Cambieri, M. and Marzatico, F. (2001) Prevention of Neuronal Cell Damage Induced by Oxidative Stress in-Vitro: Effect of Different Ginkgo Biloba Extracts. Journal of Pharmacy and Pharmacology, 53, 387-392.

[8]   Kanski, J., Aksenova, M., Stoyanova, A. and Butterfield, D.A. (2002) Ferulic Acid Antioxidant Protection Against Hydroxyl and Peroxyl Radical Oxidation in Synaptosomal and Neuronal Cell Culture Systems in Vitro: Structure-Activity Studies. The Journal of Nutritional Biochemistry, 13, 273-281.

[9]   Wei, T., Sun, H., Zhao, X., Hou, J., Hou, A., Zhao, Q. and Xin, W. (2002) Scavenging of Reactive Oxygen Species and Prevention of Oxidative Neuronal Cell Damage by a Novel Gallotannin, Pistafolia A. Life Sciences, 70, 1889-1899.

[10]   Bastianetto, S., Zheng, W.H. and Quirion, R. (2000) Neuroprotective Abilities of Resveratrol and Other Red Wine Constituents against Nitric Oxide-Related Toxicity in Cultured Hippocampal Neurons. British Journal of Pharmacology, 131, 711-720.

[11]   Hegde, M.L., Hegde, P.M., Rao, K.S. and Mitra, S. (2011) Oxidative Genome Damage and Its Repair in Neurodegenerative Diseases: Function of Transition Metals as a Double-Edged Sword. Journal of Alzheimer’s Disease, 24, 183-198.

[12]   Ihara, Y., Chuda, M., Kuroda, S. and Hayabara, T. (1999) Hydroxyl Radical and Superoxide Dismutase in Blood of Patients with Parkinson’s Disease: Relationship to Clinical Data. Journal of the Neurological Sciences, 170, 90-95.

[13]   Abraham, S., Soundararajan, C.C., Vivekanandhan, S. and Behari, M. (2005) Erythrocyte Antioxidant Enzymes in Parkinson’s Disease. Indian Journal of Medical Research, 121, 111-115.

[14]   Chen, C.-M., Liu, J.-L., Wu, Y.-R., Chen, Y.-C., Cheng, H.-S., Cheng, M.-L. and Chiu, D.-T. (2009) Increased Oxidative Damage in Peripheral Blood Correlates with Severity of Parkinson’s Disease. Neurobiology of Disease, 33, 429-435.

[15]   Moosmann, B. and Behl, C. (2002) Antioxidants as Treatment for Neurodegenerative Disorders. Expert Opinion on Investigational Drugs, 11, 1407-1435.

[16]   Ortiz, G.G., Pacheco-Moises, F.P., Gomez-Rodriguez, V.M., Gonzalez-Renovato, E.D., Torres-Sanchez, E.D. and Ramirez-Anguiano, A.C. (2013) Fish Oil, Melatonin and Vitamin E Attenuates Midbrain Cyclooxygenase-2 Activity and Oxidative Stress after the Administration of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Metabolic Brain Disease, 28, 705-709.

[17]   Paraskevas, G.P., Kapaki, E., Petropoulou, O., Anagnostouli, M., Vagenas, V. and Papageorgiou, C. (2003) Plasma Levels of Antioxidant Vitamins C and E Are Decreased in Vascular Parkinsonism. Journal of the Neurological Sciences, 215, 51-55.

[18]   Jomova, K. and Valko, M. (2011) Advances in Metal-Induced Oxidative Stress and Human Disease. Toxicology, 283, 65-87.

[19]   Zhang, Z., Zhang, K.K., Du, X.R. and Li, Y.B. (2012) Neuroprotection of Desferrioxamine in Lipopolysaccharide-Induced Nigrostriatal Dopamine Neuron Degeneration. Molecular Medicine Reports, 5, 562-566.

[20]   Sangchot, P., Sharma, S., Chetsawang, B., Porter, J., Govitrapong, P. and Ebadi, M. (2002) Deferoxamine Attenuates Iron-Induced Oxidative Stress and Prevents Mitochondrial Aggregation and α-Synuclein Translocation in SK-N-SH Cells in Culture. Developmental Neuroscience, 24, 143-153.

[21]   Scapagnini, G., Butterfield, D.A., Colombrita, C., Sultana, R., Pascale, A. and Calabrese, V. (2004) Ethyl Ferulate, a Lipophilic Polyphenol, Induces HO-1 and Protects Rat Neurons against Oxidative Stress. Antioxidant & Redox Sinaing, 6, 811-818.

[22]   Mandel, S., Maor, G. and Youdim, M.B. (2004) Iron and α-Synuclein in the Substantia Nigra of MPTP-Treated Mice: Effect of Neuroprotective Drugs R-Apomorphine and Green Tea Polyphenol (-)-epigallocatechin-3-gallate. Journal of Molecular Neuroscience, 24, 401-416.

[23]   Mukhtar, H. and Ahmad, N. (1999) Mechanism of Cancer Chemopreventive Activity of Green TEA. Proceeding of the Society for Experimental Biology and Medicine, 220, 234-238.

[24]   Zhang, M.H., Luypaert, J., Fernández Pierna, J.A., Xu, Q.S. and Massart, D.L. (2004) Determination of Total Antioxidant Capacity in Green Tea by Near-Infrared Spectroscopy and Multivariate Calibration. Talanta, 62, 25-35.

[25]   Chacko, S.M., Thambi, P.T., Kuttan, R. and Nishigaki, I. (2010) Beneficial Effects of Green Tea: A Literature Review. Chinese Medicine, 5, 13.

[26]   Sian-Hulsmann, J., Mandel, S., Youdim, M.B. and Riederer, P. (2011) The Relevance of Iron in the Pathogenesis of Parkinson’s Disease. Journal of Neurochemistry, 118, 939-957.

[27]   Schuff, N. (2009) Potential Role of High-Field MRI for Studies in Parkinson’s Disease. Movement Disorders, 24, S684-S690.

[28]   Logroscino, G., Marder, K., Graziano, J., Freyer, G., Slavkovich, V., LoIacono, N. and Mayeux, R. (1997) Altered Systemic Iron Metabolism in Parkinson’s Disease. Neurology, 49, 714-717.

[29]   Qureshi, G.A., Qureshi, A.A., Memon, S.A. and Parvez, S.H. (2006) Impact of Selenium, Iron, Copper and Zinc in on/ off Parkinson’s Patients on L-Dopa Therapy. Journal of Neural Transmission-Supplement, 71, 229-236.

[30]   Madenci, G., Bilen, S., Arli, B., Saka, M. and Ak, F. (2012) Serum Iron, Vitamin B12 and Folic Acid Levels in Parkinson’s Disease. Neurochemical Reserach, 37, 1436-1441.

[31]   Barthwal, M.K., Srivastava, N., Shukla, R., Nag, D., Seth, P.K., Srimal, R.C. and Dikshit, M. (1999) Polymorphonuclear Leukocyte Nitrite Content and Antioxidant Enzymes in Parkinson’s Disease Patients. Acta Neurological Scandinavica, 100, 300-304.

[32]   Urakami, K., Sano, K., Matsushima, E., Okada, A., Saito, H., Takahashi, K. and Ikawa, S. (1992) Decreased Superoxide Dismutase Activity in Erythrocyte in Parkinson’s Disease. The Japanese Journal of Psychiatry and Neurology, 46, 933-936.

[33]   Zou, C.P., Liu, H.G., Feugang, J.M., Hao, Z.P., Chow, H.-H.S. and Garcia, F. (2010) Green Tea Compound in Chemoprevention of Cervical Cancer. International Journal of Gynecological Cancer, 20, 617-624.

[34]   Davalli, P., Rizzi, F., Caporali, A., Pellacani, D., Davoli, S., Bettuzzi, S., Brausi, M. and D’Arca, D. (2012) Anticancer Activity of Green Tea Polyphenols in Prostate Gland. Oxidative Medicine and Cellular Longevity, 2012, Article ID: 984219.

[35]   Ellis, L.Z., Liu, W.M., Luo, Y.C., Okamoto, M., Qu, D., Dunn, J.H. and Fujita, M. (2011) Green Tea Polyphenol Epigallocatechin-3-Gallate Suppresses Melanoma Growth by Inhibiting Inflammasome and IL-1β Secretion. Biochemical and Biophysical Research Communications, 414, 551-556.

[36]   Lin, Y.-S., Tsai, Y.-J., Tsay, J.-S. and Lin, J.-K. (2003) Factors Affecting the Levels of Tea Polyphenols and Caffeine in Tea Leaves. Journal of Agricultural and Food Chemistry, 51, 1864-1873.

[37]   Kumar, P. and Kumar, A. (2009) Effect of Lycopene and Epigallocatechin-3-Gallate against 3-Nitropropionic Acid Induced Cognitive Dysfunction and Glutathione Depletion in Rat: A Novel Nitric Oxide Mechanism. Food and Chemical Toxicology, 47, 2522-2530.

[38]   Reznichenko, L., Amit, T., Youdim, M.B. and Mandel, S. (2005) Green Tea Polyphenol (-)-epigallocatechin-3-gallate Induces Neurorescue of Long-Term Serum-Deprived PC12 Cells and Promotes Neurite Outgrowth. Journal of Neurochemistry, 93, 1157-1167.

[39]   Levites, Y., Weinreb, O., Maor, G., Youdim, M.B. and Mandel, S. (2001) Green Tea Polyphenol (-)-epigallocatechin- 3-gallate Prevents N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Dopaminergic Neurodegeneration. Journal of Neurochemistry, 78, 1073-1082.

[40]   Ng, T.P., Feng, L., Niti, M., Kua, E.H. and Yap, K.B. (2008) Tea Consumption and Cognitive Impairment and Decline in Older Chinese Adults. The American Journal of Clinical Nutrition, 88, 224-231.

[41]   Cabrera, C., Artacho, R. and Gimenez, R. (2006) Beneficial Effects of Green Tea—A Review. Journal of the American College of Nutrition, 25, 79-99.

[42]   Chan, P., Qin, Z. and Zheng, Z. (2009) A Randomized, Double-Blind, Placebo Controlled, Delayed Start Study to Assess Safety, Tolerability and Efficacy of Green Tea Polyphenols in Parkinson’s Disease. Proceeding of the XVIII WFN World Congress on Parkinson’s Disease and Related Disorders, 15, S145.